Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review

Psychiatry Research

Volumn 237, Issue , 2016, Pages 257-263

  Bo, Qi Jing ^a,b   Wang, Zhi Min ^a,b   Li, Xian Bin ^a,b   Ma, Xin ^a   Wang, Chuan Yue ^a,b   de Leon, Jose ^c,d,e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c M Hlth Res Ctr at E State Hosp   (United States)

^d UNIVERSITY OF GRANADA   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Metabolic abnormalities; Prolactin; Weight gain

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; METFORMIN; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE; SULPIRIDE; ANTIDIABETIC AGENT; NEUROLEPTIC AGENT;

AMENORRHEA; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; MENSTRUATION; NAUSEA; OBSERVATIONAL STUDY; OLIGOMENORRHEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RESTLESSNESS; SCHIZOPHRENIA; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); FEMALE; MALE; PROCEDURES;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYPERPROLACTINEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PROLACTIN;

EID: 84959175714     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.01.031     Document Type: Article

References (49)

1. Baptista T., LaCruz A., Meza T., Contreras Q., Delgado C., Mejías M.A., Hernández L. Antipsychotic drugs and obesity: Is prolactin involved?. Can. J. Psychiatry 2001, 46:829-834.
2. Baptista T., ElFakih Y., Uzcátegui E., Sandia I., Tálamo E., Araujo de Baptista E., Beaulieu S. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008, 22:477-495.
3. Bhattacharjee J., El-Sayeh H.G. Aripiprazole versus typicals for schizophrenia. Cochrane Database Syst. Rev. 2008, 16:CD006617.
4. Billa E., Kapolla N., Nicopoulou S.C., Koukkou E., Venaki E., Milingos S., Antsaklis A., Adamopoulos D.A. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol. Endocrinol. 2009, 25:427-434.
5. Biller B., Luciano A., Crosignani P., Molitch M., Olive D., Rebar R., Sanfilippo J., Webster J., Zacur H. Guidelines for the diagnosis and treatment of hyperprolactinemia. J. Reprod. Med. 1999, 44:1075-1084.
6. Bostwick J.R., Guthrie S.K., Ellingrod V.L. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009, 29:64-73.
7. Bushe C., Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J. Psychopharmacol. 2007, 21:768-773.
8. Bushe C., Shaw M., Peveler R.C. A review of the association between antipsychotic use and hyperprolactinaemia. J. Psychopharmacol. 2008, 22:46-55.
9. Bushe C.J., Bradley A.J., Wildgust H.J., Hodgson R.E. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr. Res. 2009, 114:6-16.
10. Byerly M., Suppes T., Tran Q.V., Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 2007, 27:639-661.
11. Correll C.U., Sikich L., Reeves G., Riddle M. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?. Am. J. Psychiatry 2013, 170:947-952.
12. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003, 60:553-564.
13. Ehret M., Goethe J., Lanosa M., Coleman C.I. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J. Clin. Psychiatry 2010, 71:1286-1292.
14. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter.Y., Alonso-Coello P., Schünemann H.J., GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 2008, 336:924-926.
15. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
16. Halbreich U., Kahn L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J. Psychiatr. Pract. 2003, 9:344-353.
17. Hoffer Z.S., Roth R.L., Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009, 50:317-324.
18. Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. Aust. N.Z J. Psychiatry 2011, 45:830-837.
19. Jarskog L.F., Hamer R.M., Catellier D.J., Stewart D.D., Lavange L., Ray N., Golden L.H., Lieberman J.A., Stroup T.S., METS Investigators Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2013, 170:1032-1040.
20. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., Sun W., Carson W.H., Pikalov A., Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatry 2009, 70:1348-1357.
21. Kim E.Y., Kim S.H., Lee N.Y., Jung D.C., Kim Y.S., Ahn Y.M. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry 2012, 45:57-63.
22. Kishimoto T., De Hert M., Carlson H.E., Manu P., Correll C.U. Osteoporosis and fracture risk in people with schizophrenia. Curr. Opin. Psychiatry 2012, 25:415-429.
23. Krysiak R., Okrzesik J., Okopien B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2015, 49:242-249.
24. Leandro, G. 2008. Meta-analysis in Medical Research: The Handbook for the Understanding and Practice of Meta-analysis. Wiley.com. Available from: (accessed May 2015). http://www.books.google.com.
25. Lehman A.F., Lieberman J., Dixon L., McGlashan T., Miller A., Perkins D.O., Kreyenbuhl J., American Psychiatric Association, Steering Committee on Practice Guidelines Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 2004, 161(2 Suppl):1-56.
26. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166:152-163.
27. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lässig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
28. Li X., Tang Y., Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One 2013, 8:e70179.
29. Liang C.S. Effect of metformin on antipsychotic drug-induced galactorrhea-amenorrhea syndrome. China Mod. Med. 2013, 20:54-56. [In Chinese].
30. Linneke J.L., Jorgensen G.K., Csillag C. Metformin for weight loss and control in patients with mood disorder. J. Clin. Psychiatry 2014, 75:e1140-e1141.
31. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin. Pharm. 1992, 11:851-856.
32. Matevosyan N.R. Schizophrenia and Stein-Leventhal syndrome: comorbidity features. Arch. Gynecol. Obstet. 2011, 284:1035-1041.
33. Meyer J.M. Antipsychotics and metabolics in the post-CATIE era. Curr. Top. Bevav. Neurosci. 2010, 4:23-42.
34. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269.
35. Musil R., Obermeier M., Russ P., Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert. Opin. Drug. Saf. 2015, 14:73-96.
36. Nordstrom A.L., Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J. Clin. Psychopharmacol. 1998, 18:305-310.
37. Nunes L.V., Moreira H.C., Razzouk D., Nunes S.O., Mari J., de J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J. Sex. Marital. Ther. 2012, 38:281-301.
38. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J. Psychopharmacol. 2008, 22:70-75.
39. Ortega-Gonzalez C., Cardoza L., Coutino B., Hidalgo R., Arteaga-Troncoso G., Parra A. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J. Endocrinol. 2005, 184:233-239.
40. Ried K. Interpreting and understanding meta-analysis graphs - a practical guide. Aust. Fam. Phys. 2006, 35:635-638.
41. Shi W., Ding S.E. Preliminary observation of the metformin in efficacy for hyperprolactinemia induced by antipsychotics. J. Clin. Psychiatry 2013, 23:408-409. [In Chinese].
42. Shim J.C., Shin J.G., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., Shon J.H., Conley R.R. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am. J. Psychiatry 2007, 164:1404-1410.
43. Smith R.C. Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia. Am. J. Psychiatry 2012, 169:774-776.
44. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43:647-654.
45. Wang C.Y., Xiang Y.T., Cai Z.J., Weng Y.Z., Bo Q.J., Zhao J.P., Liu T.Q., Wang G.H., Weng S.M., Zhang H.Y., Chen D.F., Tang W.K., Ungvari G.S., Risperidone Maintenance Treatment in Schizophrenia (RMTS) investigators Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am. J. Psychiatry 2010, 167:676-685.
46. Wu R.R., Jin H., Gao K., Twamley E.W., Ou J.J., Shao P., Wang J., Guo X.F., Davis J.M., Chan P.K., Zhao J.P. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 2012, 169:813-821.
47. Yamada K., Kanba S., Yagi G., Asai M. Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. J. Clin. Psychopharmacol. 1999, 19:380-381. [In Chinese].
48. Yuan H.N., Wang C.Y., Sze C.W., Tong Y., Tan Q.R., Feng X.J., Liu R.M., Zhang J.Z., Zhang Y.B., Zhang Z.J. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J. Clin. Psychopharmacol. 2008, 28:264-370.
49. Yum S.K., Kim T., Hwang M.Y. Polycystic ovaries is a disproportionate signal in pharmacovigilance data mining of second generation antipsychotics. Schizophr. Res. 2014, 158:275-276.